SYMBIOTEC

- Symbiotec Pharmalab Limited informed the exchange regarding the availability of the audio recording for the earnings conference call held on November 06, 2026. - The audio recording link has been made accessible on the company's official website under the investors section.

Order Win: Symbiotec Pharmalab won a 10-year, take-or-pay agreement from a European alternative protein innovator to manufacture fermentation-based alternative protein Order Value: Not disclosed due to confidentiality obligations Completion Timeline: 10 years with dedicated capacity reservation at the Ujjain campus

- Q2 FY27 Consolidated Revenue increased 43% YoY to ₹280 Cr. - Consolidated EBITDA grew 88% YoY to ₹94 Cr; PAT surged 169% YoY to ₹52 Cr. - API revenue grew 16% YoY to ₹227 Cr with EBITDA margins steady at ~30%. - Recognized ₹53 Cr milestone revenue from US Complex Injectables licensing deal.

- Q2 FY27 Consolidated Revenue rose 43% YoY to ₹280 Cr; PAT surged 169% YoY to ₹52 Cr. - Recognized ₹53 Cr milestone revenue from US DCV licensing agreement. - In advanced stages for a 10-year CDMO take-or-pay contract. - Over ₹1,000 Cr capex in new businesses to commence revenue in 6–12 months.

Q2 FY27 Consolidated Revenue ₹280 Cr vs ₹196 Cr (▲43% YoY) EBITDA ₹92 Cr vs ₹50 Cr (▲82% YoY) PAT ₹52 Cr vs ₹19 Cr (▲169% YoY) EBITDA Margin 33% vs 26% (▲700bps)

Concall Schedule Concall Date: Friday, 6 November 2026 Concall Time: 09:30 AM (IST)

Order Win: Symbiotec's wholly owned subsidiary Knovea Pharmaceutical won a strategic commercialization agreement from a leading global pharmaceutical company Order Value: Not disclosed due to confidentiality (addresses a U.S. market estimated at approximately US$288 million) Completion Timeline: Long-term agreement with milestone payments through development, regulatory approval, and commercial launch, alongside profit-sharing from launch onwards

Order Win: Symbiotec Pharmalab Limited's subsidiary Knovea Pharmaceutical entered into a strategic commercialization agreement with a leading global pharmaceutical company Order Value: Addresses a U.S. market estimated at approximately US$288 million Completion Timeline: Long-term agreement with milestone payments through development, regulatory approval, and commercial launch, alongside profit-sharing from launch onwards.

- Symbiotec Pharmalab Limited received the Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility located in Pithampur (SEZ), Madhya Pradesh. - The inspection classification is Voluntary Action Indicated (VAI). - The inspection was conducted from August 10, 2026, to August 14, 2026.